...
首页> 外文期刊>Seminars in pediatric neurology >Current strategies in the management of lysosomal storage diseases.
【24h】

Current strategies in the management of lysosomal storage diseases.

机译:溶酶体贮积病管理中的当前策略。

获取原文
获取原文并翻译 | 示例

摘要

Lysosomal storage diseases (LSDs) comprise a diverse group of over 40 clinically distinct inherited disorders. LSDs are progressive and may present at any age affecting any number of tissues and organ systems. They result from a genetic defect in cellular transport or metabolism of molecules within the lysosome. Treatment is directed toward symptomatic care of secondary complications for most of these diseases. For some individuals, hematopoietic stem cell transplantation or enzyme-replacement therapy can be effective. However, limitations in these therapies still exist. To date, there is no cure for any of the LSDs. Early diagnosis and treatment is essential for optimal treatment; this lends support to implementing mass newborn screening for LSDs.
机译:溶酶体贮积病(LSD)包含40多种临床上不同的遗传性疾病。 LSD是进行性的,可以在任何年龄出现,影响任何数量的组织和器官系统。它们是由溶酶体内分子的细胞运输或代谢的遗传缺陷引起的。治疗针对这些疾病中大多数继发并发症的对症治疗。对于某些人,造血干细胞移植或酶替代疗法可能是有效的。但是,这些疗法仍然存在局限性。迄今为止,还没有治愈任何LSD的方法。早期诊断和治疗对于最佳治疗至关重要。这为实施大规模的LSD新生儿筛查提供了支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号